LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorHealthcare

20.95 3.61

Buy Sell

Overview

Share price change

24h

Current

Min

20.12

Max

21.13

Key metrics
By Trading Economics
Income	102K -128M
EPS	-0.69
Employees	507
EBITDA	-9.8M -135M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+75.66% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-4.1M 3B
Previous open	17.34
Previous close	20.95

News Sentiment

By Acuity

76%

24%

310 / 344 Healthcare

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 May 2026, 22:47 UTC

Earnings

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 May 2026, 20:45 UTC

Earnings

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 May 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 May 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 May 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 May 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 May 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 May 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 May 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 May 2026, 22:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 May 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 May 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 May 2026, 21:12 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 May 2026, 21:00 UTC

Earnings

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 May 2026, 20:57 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 May 2026, 20:55 UTC

Earnings

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 May 2026, 20:48 UTC

Hot Stocks

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 May 2026, 20:34 UTC

Earnings

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 May 2026, 20:31 UTC

Earnings

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 May 2026, 20:28 UTC

Earnings

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 May 2026, 20:26 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 May 2026, 20:20 UTC

Earnings

Costco 3Q Membership Fees $1.37B

28 May 2026, 20:20 UTC

Earnings

Costco 3Q Net Sales $69.15B

28 May 2026, 20:19 UTC

Earnings

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 May 2026, 20:19 UTC

Earnings

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 May 2026, 20:17 UTC

Earnings

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 May 2026, 20:17 UTC

Earnings

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

75.66% upside

12 Months Forecast

Average 35.5 USD 75.66%

High 42 USD

Low 23 USD

Based on 13 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

310 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.